Welcome to our dedicated page for Xtant Medical Holdings SEC filings (Ticker: XTNT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Xtant Medical Holdings's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Xtant Medical Holdings's regulatory disclosures and financial reporting.
Xtant Medical Holdings (XTNT) reported new equity awards to its Chief Operating Officer on a Form 4. On 11/15/2025, the officer acquired 292,253 shares of common stock at a price of $0 through a deferred stock unit (DSU) award, bringing total beneficial ownership of common stock to 670,866 shares held directly. The DSU grant will vest in four installments: 73,063 shares on each of November 15, 2026, November 15, 2027, and November 15, 2028, and 73,064 shares on November 5, 2029, subject to continued employment, with settlement of shares deferred under the award terms.
The filing also reports a grant of 584,506 performance stock units (PSUs) at a price of $0, which represent a contingent right to receive an equal number of common shares. These PSUs can vest in one-third increments based on stock price performance goals over a three-year period and additional service-based conditions, with 584,506 derivative securities beneficially owned following the grant. The footnotes note that existing holdings include shares issuable under prior RSU and DSU awards from the company’s equity incentive plans.
Xtant Medical Holdings reported an equity award to its CFO and Assistant Secretary. On 11/15/2025, the executive received 263,291 deferred stock units (DSUs) at a price of $0, increasing his beneficial ownership of common stock to 851,465 shares held directly.
The DSUs vest in installments of 65,822 shares on each of November 15, 2026, November 15, 2027, and November 15, 2028, and 65,825 shares on November 5, 2029, subject to continued employment, with settlement deferred under the award terms. The filing also reports 526,582 performance stock units (PSUs), representing 200% of a 263,291-share target, which can convert into common stock based on stock price performance over a three-year period and additional service-based vesting conditions.
Xtant Medical Holdings (XTNT) furnished an update on its business by announcing financial results for the three and nine months ended September 30, 2025. The results are provided in a press release attached as Exhibit 99.1 and are furnished, not filed, under the Exchange Act.
The company highlighted its use of non‑GAAP adjusted EBITDA, defined as net income (loss) from operations before depreciation and amortization, interest, and taxes, further adjusted for separation‑related expenses, non‑cash compensation, divestiture/acquisition‑related expenses, acquisition‑related fair value adjustments, and unrealized foreign currency translation gains or losses.
Xtant notes that adjustments include expenses tied to its pending divestiture of non‑core Coflex/CoFix assets and its international hardware business. A reconciliation to GAAP metrics appears in the press release.
Xtant Medical Holdings (XTNT) reported a profitable Q3 2025. Total revenue was $33.3 million, up from $27.9 million a year ago, driven by $27.8 million of product sales and $5.5 million of license revenue. Gross margin improved to 66.1% from 58.4%, and net income reached $1.3 million versus a $5.0 million loss last year.
For the nine months, revenue rose to $101.6 million from $85.8 million and net income was $4.9 million compared with a $13.3 million loss. Cash and cash equivalents were $10.4 million as of September 30, 2025, with $11.3 million drawn on the line of credit and $17.4 million of long‑term debt. Share count was 140,004,240 as of November 7, 2025.
The company received $7.5 million in non‑refundable deposits tied to the pending sale of Coflex/CoFix assets and its international hardware business and prepaid a portion of its term loan under MidCap consents. U.S. sales accounted for about 91% of revenue; bill‑and‑hold contributed $0.6 million in the quarter.
Xtant Medical Holdings reported results from its November 7, 2025 annual meeting. Stockholders approved an amendment to the 2023 Equity Incentive Plan to increase the shares available under the plan by 12,300,000, effective immediately upon approval.
Shareholders also elected all nominated directors and approved other proposals, including advisory votes on executive compensation and auditor matters. The Board set the say‑on‑pay frequency at one year. A quorum was present with 96,880,348 shares represented, or 69.2% of shares outstanding as of the record date. Shares outstanding were 140,000,485 as of September 9, 2025.
Xtant Medical Holdings, Inc. (XTNT) filed a definitive proxy statement for the November 7, 2025 annual meeting that includes election of directors and a stockholder vote on an amendment to the 2023 Equity Incentive Plan. The amendment would increase shares available for grant under the 2023 Plan from 4,167,444 to 16,467,444, with reported current dilution metrics of 6.9% current dilution and 9.9% current potential dilution (overhang), and a potential dilution of 18.7% as a percentage of shares outstanding. The filing discloses directors and committee memberships, director and executive equity and cash compensation elements, aggregate equity awards outstanding (9,726,682 total equity awards outstanding), and common stock outstanding (140,000,485). Named executive officer grant and total compensation figures for 2023 and 2024 are provided, along with plan governance terms describing Award types, vesting, Change in Control treatment, Committee authority, and share counting rules. The proxy also lists beneficial ownership for executives and directors and describes insider trading and grant-timing practices.
Sean E. Browne, President and CEO and a director of Xtant Medical Holdings, Inc. (XTNT), reported a transaction dated 08/15/2025 in which 10,605 common shares were surrendered to the issuer to satisfy tax withholding obligations upon vesting of restricted stock units at a reported price of $0.63 per share. After the withholding, the filing shows 2,180,337 shares beneficially owned, which includes 818,740 shares issuable upon future vesting of restricted stock or deferred stock units under the 2023 Equity Incentive Plan, conditioned on continued employment. The Form 4 was executed by an attorney-in-fact on 08/19/2025.
Insider transaction summary: This Form 4 reports that Neils Scott C, identified as the company's Chief Financial Officer and a director of Xtant Medical Holdings, Inc. (XTNT), had 34,131 shares disposed on 08/15/2025 under transaction code F at a price of $0.63 per share. The filing states these shares were withheld by the issuer to satisfy tax withholding obligations upon vesting of restricted stock units. After the transaction, the reporting person beneficially owned 588,174 shares, which includes 235,623 shares issuable under the 2023 Equity Incentive Plan and 85,220 shares issuable under the Amended and Restated 2018 Equity Incentive Plan, all conditioned on continued employment through vesting. The form is signed by an attorney-in-fact and dated 08/19/2025.
Xtant Medical Holdings reported improved operating results for the quarter ended June 30, 2025 with total revenue of $35.4 million, up 18% from the prior-year quarter, driven by higher orthobiologics sales and $5.0 million of license revenue recognized in the quarter. Gross profit rose to $24.3 million, lifting gross margin to 68.6% from 62.1% a year earlier, reflecting better sales mix, scale and lower product costs. The company posted net income of $3.55 million for the quarter, reversing a prior-year loss.
On the balance sheet, total assets increased to $103.5 million and stockholders' equity to $48.5 million. Cash and restricted cash at period end totaled $7.04 million. The company remains levered with a $22.3 million term loan (net of issuance costs) and a $12.0 million outstanding on its revolving line of credit, and it reported compliance with credit covenants. Subsequent to period end, Xtant entered agreements to sell its Coflex/CoFix U.S. business for $17.5 million (with a non-refundable $2.5 million deposit received) and Paradigm Spine GmbH for $1.7 million, both closings contingent on buyer financing and subject to customary adjustments.
Xtant Medical Holdings, Inc. announced its financial results for the three and six months ended June 30, 2025 and furnished a related press release and investor presentation as exhibits to this Current Report.
The company explained its use of a non-GAAP adjusted EBITDA metric, defined as net income (loss) before depreciation and amortization, interest and tax benefit (expense), and further adjusted to add back or exclude separation-related expenses, non-cash compensation, divestiture/acquisition-related expenses, acquisition-related fair value adjustments, and unrealized foreign currency translation gains or losses. The press release reconciles this non-GAAP measure to GAAP net income. The filing also discloses a pending divestiture of its non-core Coflex/CoFix spinal implants and international business and notes that furnished materials are provided pursuant to Regulation FD.